Pharmacoeconomic Analysis of Cefmenoxime Dual Individualization in the Treatment of Nosocomial Pneumonia
Authors:
- Robert E. FellRFRobert E. Fell
- 1 March 1994
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 28 (3) , 384-389
Abstract
OBJECTIVE: To determine if dual individualization of cefmenoxime dosing is cost-effective. DESIGN: Retrospective, pharrnacoeconomic decisionanalysis of two consecutively conductedprospective clinical studies. PATIENTS: Patientswithdocumentedgram-negative nosocomial pneumoniawere evaluated. Thirty-three patients received cefmenoximeat standarddosing and 28 patients received doses according to dual individualization methodology. MAIN OUTCOME MEASURE: Antibiotic and infection-related costs were compared between groups. The number of hospital antibiotic days and costs incurred on those days were also evaluated. A decision model was constructed to characterize differences in treatment outcome. Probabilities with in the decision tree were derived from 61 evaluable patients. Cost-effectiveness and incremental cost-effectiveness ratios were calculated. Sensitivity analysis was performed by varying out come probabilities, antibiotic prices, and hospital room costs. RESULTS: Antibiotic and infection-related costs (mean ± SEM) were $848 ± 78 for standard cefmenoxime dosing and $1123 ± 128 for dual individualization (p0.05). Median antibiotic length of stay (ALOS) was 15.2 and 12.7 days for standard and dual individualization methodologies, respectively (p>0.05). Incremental analysis of cost effectiveness indicated that a similar reduction in length of stay for 259 dual individualization patients would save $321 808 annually. CONCLUSIONS: Sensitivity analysis indicates that by reducing ALOS, dual individualization could be a cost-effective method of betalactam dosing for patients with pneumonia. A prospective study should be conducted to validate these findings.Keywords
This publication has 21 references indexed in Scilit:
- Economic Aspects of Pharmacokinetic ServicesPharmacoEconomics, 1993
- Regulation of the Pharmaceutical IndustryPharmacoEconomics, 1992
- Nosocomial Pneumonia in Medicare PatientsArchives of internal medicine (1960), 1991
- Impact of Diagnosis-Related Groups' Prospective Payment on Utilization of Medical Intensive CareChest, 1988
- Financial Implications of Prolonged Ventilator Care of Medicare Patients under the Prospective Payment SystemChest, 1987
- APACHE IICritical Care Medicine, 1985
- Role for Dual Individualization with CefmenoximeThe American Journal of Medicine, 1984
- Management of Pneumonia in the Prospective Payment EraArchives of internal medicine (1960), 1984
- Cefmenoxime in the treatment of nosocomial pneumonias in critical care patientsJournal of Antimicrobial Chemotherapy, 1984
- Deaths from nosocomial infections: Experience in a university hospital and a community hospitalThe American Journal of Medicine, 1980